Anavex Life Sciences has released encouraging preliminary data from its
48-week open-label extension Phase 2 study of ANAVEX®2-73 (blarcamesine) in
patients with Parkinson’s disease dementia. This study has shown that
ANAVEX®2-73 offers significant clinical benefits by improving various efficacy
endpoints over the study period.
Parkinson’s disease is a chronic and progressive neurological disorder affecting millions
worldwide. Anavex Life Sciences is committed to developing innovative
therapeutics for this debilitating condition. The 48-week Phase 2 study
assessed the safety, tolerability, and efficacy of ANAVEX®2-73. The results
revealed substantial improvements in patients’ clinical symptoms as measured by
the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale
(MDS-UPDRS), REM Sleep Behavior Disorder Screening Questionnaire (RBDSQ), and
the Montreal Cognitive Assessment (MoCA).
Dr. Christopher U Missling, CEO of Anavex, remarked on the significance of these findings, noting the potential of
ANAVEX®2-73 to slow and possibly reverse symptoms of Parkinson’s disease. This
aligns with previous successful outcomes in the double-blind,
placebo-controlled Phase 2 study, which also demonstrated significant
improvements in MDS-UPDRS scores.
The study’s preliminary safety analysis indicated that ANAVEX®2-73 was generally
well-tolerated, with a safety profile consistent with earlier studies. Anavex
Life Sciences plans to proceed with a pivotal trial to further explore the
therapeutic potential of ANAVEX®2-73 for Parkinson’s disease.
In addition to Parkinson’s disease, Anavex
Life Sciences is exploring the efficacy of ANAVEX®2-73 in treating other neurodegenerative and
neurodevelopmental disorders, including Alzheimer’s disease and Rett syndrome.
Their research is supported by grants, including one from the Michael J. Fox
Foundation for Parkinson’s Research.
Anavex Life Sciences continues to advance the field of neurotherapeutics, with its
dedication to evidence-based innovations offering hope to millions affected by
debilitating CNS disorders. Visit this page on LinkedIn, for additional information.
Find more about Anavex on https://www.biospace.com/article/releases/anavex-life-sciences-initiates-placebo-controlled-u-s-phase-2-clinical-trial-of-anavex-3-71-in-schizophrenia/